TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01866657
Drug: Vasoconstrictor Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: cerebral desaturations may be treated with IV vasoactives to increase blood pressure or cardiac output at attending physician's descretion.
Study: NCT01866657
Drug: Additional anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: By deepening anesthetic there will be a decrease in cerebral metabolic oxygen consumption.
Study: NCT01866657
Drug: Increase FiO2
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase FiO2 to improve oxygen delivery to tissue
Study: NCT01421186
Drug: MOR03087
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOR03087 will be administered according to the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen for MOR03087 from parts A-E of the phase I dose escalation. The biweekly MOR03087 regimen as described in part A; the weekly regimen as described for parts B-E.
Study: NCT02126267
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (500 mg) once daily for 3 consecutive days.
Study: NCT02939742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
Study: NCT00978250
Drug: 5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FdCyd, a fluoropyrimidine nucleoside analog, has a short (10-minute) half-life and is rapidly degraded in vivo by cytidine deaminase. However, co-administration with THU, an inhibitor of cytidine/deoxycytidine deaminase, has been shown to increase the area under the curve (AUC) of the parent compound more than 4-fold. Increased FdCyd exposure allows it to be taken up intracellularly and converted to its triphosphate, which is incorporated into deoxyribonucleic acid (DNA) and inhibits the action of the enzyme DNA methyltransferase (DNMT). Inhibition of DNMT, and in turn DNA methylation, can result in the re-expression of tumor suppressor genes.
Study: NCT02272725
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen
Study: NCT02272725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tasteless and inert visually identical (to ibuprofen) pills
Study: NCT00185692
Drug: Solumedrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg IV 2 hours prior to ATG Used to treat severe inflamation
Study: NCT00185692
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg PO, 30 minutes prior to infusion Pain reliever
Study: NCT00185692
Drug: Diphenydramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg IV, 30 minutes prior to infusion Used to relieve allergy symptoms
Study: NCT00185692
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg IV, 1 hour prior to infusion Used to relieve itching, redness and swelling of the skin
Study: NCT01470209
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKM120 (20mg to 100mg) will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. BKM120 will be administered on a continuous once daily dosing schedule. Patients should be instructed to take the dose of BKM120 daily in the morning, one hour after a light breakfast (morning meal) at approximately the same time each day. BKM120 should be taken with a glass of water and consumed over as short a time as possible. Patients should swallow the capsules as a whole and not chew them. Patients should continue to fast for 2 hours after the administration of each BKM120 dose.
Study: NCT01313143
Drug: AOP200704
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of AOP200704 with Esmolol
Study: NCT03925233
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin Hydrochloride Injection
Study: NCT03925233
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil injection
Study: NCT03925233
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate injection
Study: NCT03925233
Drug: Pattozumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pattozumab injection
Study: NCT03925233
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine tablets
Study: NCT03925233
Drug: Ear particles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ear particles
Study: NCT03925233
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide injection
Study: NCT00045708
Drug: Anticonvulsant
Normalized name: Anticonvulsant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs that induce hepatic Metabolic enzymes
Study: NCT03884517
Drug: BAT8003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1 dose titration study from BAT8003 0.2mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
Study: NCT03173742
Drug: T1, T2, T3
Approvals — FDA: no, EMA: no, PMDA: no
Description: T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
Study: NCT03173742
Drug: T1,T3,T2
Approvals — FDA: no, EMA: no, PMDA: no
Description: T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
Study: NCT03173742
Drug: T2,T1,T3
Approvals — FDA: no, EMA: no, PMDA: no
Description: T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
Study: NCT03173742
Drug: T2,T3,T1
Approvals — FDA: no, EMA: no, PMDA: no
Description: T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
Study: NCT03173742
Drug: T3,T1,T2
Approvals — FDA: no, EMA: no, PMDA: no
Description: T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
Study: NCT03173742
Drug: T3,T2,T1
Approvals — FDA: no, EMA: no, PMDA: no
Description: T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
Study: NCT01040195
Drug: Methotrexate, Hydroxychloroquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate will be prepared as unmarked tablets of 2.5 mg strength each and Hydroxychloroquine as unmarked tablet of 200 mg strength. Patients will be started on Methotrexate/placebo at 10 mg once weekly and increased every week by 2.5 mg to maximum dose of 20 mg per week in the absence of side effects. These patients will also be started on Hydroxychloroquine 200 mg per day or placebo.
Study: NCT01040195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebos (for methotrexate and hydroxychloroquine)will be prepared and prescribed in identical fashion as the methotrexate and hydroxychloroquine in the combination DMARD arm.
Study: NCT02357004
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg daily in addition to normal BP medications
Study: NCT04128293
Drug: GSK3640254 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
Study: NCT01595867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose (100 mg) placebo tablets crushed; single dose
Study: NCT04724343
Drug: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage adjustment according to the ovarian response.
Study: NCT01940900
Drug: E10030
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01063270
Drug: Clindamycin & Rifampin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 300mg twice daily for 10 weeks and Rifampin 300mg twice daily for 10 weeks
Study: NCT00342381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose placebo treatment
Study: NCT03852628
Drug: Placebo (SL pill qd, IM injection q4weeks)
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SL placebo (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8) IM Placebo
Study: NCT00464516
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily for 14 days orally
Study: NCT03065959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03391765
Drug: Placebo solution for IV infusion on Day 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl injection/solution for infusion 500 mL; participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.
Study: NCT03115294
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iv injection
Study: NCT03896009
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam taken once upon onset of a qualifying migraine.
Study: NCT03896009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken once upon onset of a qualifying migraine.
Study: NCT04210388
Drug: AZD5718 tablet, Formulation A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteers will receive single doses of AZD5718 tablet, Formulation A under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
Study: NCT04210388
Drug: AZD5718 tablet, Formulation B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteers will receive single doses of AZD5718 tablet, Formulation B under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
Study: NCT04210388
Drug: AZD5718 tablet, Formulation C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
Study: NCT04210388
Drug: AZD5718 tablet, Formulation D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteers will receive single doses of AZD5718 tablet, Formulation D under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
Study: NCT01005914
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
Study: NCT01005914
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 4: 50 mg/m2 IV over 2 hours
Study: NCT01005914
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion
Study: NCT04210388
Drug: AZD5718 film-coated tablet, Reference treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteers will receive single doses of AZD5718 film-coated tablet, Reference treatment under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
Study: NCT04257032
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet
Study: NCT04257032
Drug: Rosuvastatin + BI 1323495
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT00186966
Drug: Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Detailed Description section for details of treatment interventions.
Study: NCT02695004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02113150
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: renal function
Study: NCT02770404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV matching placebo
Study: NCT02262689
Drug: GSK2256294
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2256294 will be supplied as gelatin capsule to be administered orally with the unit dose 5 mg / dose level 15 mg
Study: NCT02262689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo will be supplied as gelatin capsule to be administered orally
Study: NCT00437645
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules
Study: NCT00404547
Drug: Usual Care Inhaled Glucocorticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual asthma care and dosage as chosen by the Primary Care Physician including inhaled steroid treatment
Study: NCT02655016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT02957435
Drug: eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (Single arm) Sequence 1: one eplerenone coated tablet 25 mg in fasting (period 1), one eplerenone coated tablet 50 mg in fasting (period 2) and two eplerenone coated tablets 50 mg (100 mg of eplerenone) in fasting (period 3)
Study: NCT00041977
Drug: doxycycline hyclate 20 mg twice daily
Normalized name: doxycycline hyclate 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01061333
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone placebo twisthaler, Nedocromil placebo metered dose inhaler, Montelukast placebo tablet
Study: NCT00003578
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003578
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003084
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin IV on days 1, 15, and 29.
Study: NCT02289547
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: maintenance capecitabine therapy after six cycles of XELOX
Study: NCT00327002
Drug: LY518674
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00688701
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Study: NCT04645901
Drug: Drug: SYHA1805 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets of SYHA1805 with several doses
Study: NCT04645901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets of placebo with matching several doses
Study: NCT04589546
Drug: Nicotinamide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (500 mg) will be mixed in 50 ml of 0.9% saline and administered intravenously every 12 h for a total of 72 h.
Study: NCT04589546
Drug: placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the placebo group, an identical volume of 0.9% saline will be administered in the same manner.
Study: NCT02222363
Drug: VLX600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a dose of VLX600 by 4-hr intravenous infusion using a central venous catheter on Days 1, 8, and 15 of each 28-day treatment cycle. There are the following dose cohorts: 10, 20, 40, 80, 160, and 210 mg VLX600. It is anticipated that patients will receive 6 treatment cycles. In the absence of unacceptable toxicity and disease progression, patients have the option of continuing treatment beyond 6 cycles, if the investigator determines that the patient may benefit further from it.
Study: NCT00251303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules matched active drug in appearance.
Study: NCT00026442
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05386667
Drug: Majezik %0.25 oral spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day.
Study: NCT02988440
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDR001 will be administered intravenously
Study: NCT00453531
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03426865
Drug: Axumin PET scan
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET scan prior to RPLND
Study: NCT02280031
Drug: Acetylsalicylic Acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule containing Acetylsalicylic Acid 80mg pill with lactose
Study: NCT03609099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a day oral treatment during 3 days.
Study: NCT02047994
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who are positive with Helicobacter pylori in Group1 will receive triple therapy.~* Esomeprazole 40 mg bid for 10 days~* Clarithromycin 500 mg bid for 10 days~* Amoxicillin 1000 mg bid for 10 days
Study: NCT01373931
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01373931
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01583959
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid tablets 5 mg
Study: NCT02572596
Drug: CTX
Normalized name: CTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTX 2.5/m2 for 2 days.
Study: NCT01583959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo to folic acid 5 mg tables, to be given for 4 days a week
Study: NCT00811785
Drug: Copper Histidine
Normalized name: Histidine
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily subcutaneous injections for three years
Study: NCT00985725
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, once daily
Study: NCT00504725
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03895411
Drug: betaloc
Normalized name: Betaloc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral betaloc 0.5mg/kg/time ,pre 12h
Study: NCT03320018
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline 200 mg will be mixed with normal saline and given by i.v. administration, or provided as capsules for the patient to swallow, q 24 hours for 5 days.~Once patients regain the ability to swallow capsules, minocycline will be given orally in capsule form (2 capsules of 100 mg each), administered once daily for the remainder of the 5 day period.
Study: NCT00659490
Drug: AZD1940
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800ug oral administration
Study: NCT00659490
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500mg oral administration
Study: NCT00659490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given pre-surgery
Study: NCT00827541
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline 50 or 100 mg intravenously. Therapy conducted according to the package leaflet of Tygacil and to international treatment guidelines. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
Study: NCT00801281
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750 mg/m2 i.v. d. 1 q. 21 d.
Study: NCT00801281
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m2 i.v. d. 1 q. 21 d.
Study: NCT02706886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (sterile saline: 0.9% sodium chloride \[NaCl\]) will be administered SC once in Part A. In Part B matching placebo will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).
Study: NCT01264237
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90mg Tablet QD at 10:00a.m.
Study: NCT01264237
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet QD at 10:00a.m.
Study: NCT02274454
Drug: Calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium will be applied to the myometrial strips in 3 concentrations; 1.25mM (low), 2.5mM (normal) and 5.0mM (high). Myometrial strips will be either oxytocin pretreated, or non-oxytocin pretreated.
Study: NCT03716375
Drug: Intrapleural Medications
Normalized name: INTRAPLEURAL MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: urokinase
Study: NCT00336791
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FAC and FEC Chemotherapy:~500 mg/m\^2 IV on day 1 of 21 day cycle.